Expression in differentiated airway cultures
Representative microscopy from iPSC-derived air–liquid interface research. Evidence is model- and condition-specific; not a universal efficiency claim.
NCPPs · Research use only
A different way into cells.
Non-viral. Non-lipid. Nucleic-acid delivery. Non-Canonical Peptide Particles (NCPPs) are a branched-peptide research platform for delivering plasmid DNA and evaluating other nucleic-acid cargoes in challenging biological systems.
See delivery in differentiated airway tissues and mouse lung, explore the underlying chemistry, or order pre-formulated RUO particles directly. Custom formulation, catalogue and OEM partnerships are also available for discussion.
Non-viral / non-lipidBranched peptide delivery architecture
Differentiated ALIReporter expression shown in complex airway models
In vivo researchMouse pulmonary expression observed
Australian IPPatent-protected research platform
Experimental evidence
Start with the results.
The scientific case is in the biology. NCPP formulations have been evaluated in differentiated airway cultures, primary human cells, conventional cell lines and mouse pulmonary studies. Results are formulation- and model-dependent.
Pulmonary expression in mice
Bioluminescence following local airway delivery of reporter DNA in a research model.
01 / AIRWAY
Complex tissue models
Reporter expression observed in differentiated airway epithelium, including settings in which a lipid comparator showed no detectable signal under the tested conditions.
02 / CELL HEALTH
Measured, not assumed
ALI LDH experiments showed low injury under selected conditions. Other cell types and concentrations can behave differently; dose optimisation matters.
03 / RESEARCH
Beyond one reporter
Historical work includes GFP, luciferase, LacZ and CFTR-related assays, with studies across multiple research groups.
What makes NCPP different
Delivery is only the beginning.
From nucleic-acid assembly to cellular entry, particle handling and cell health: a practical platform backed by measured experiments.
Non-canonical cellular entry
Mechanistic studies in tested formulations indicate uptake outside classical clathrin- and caveolin-mediated pathways; selected PEG formulations show dynamin II dependence. Pathways can vary with formulation and cell model.
Measured room-temperature stability
Selected 2 kDa and 5 kDa PEG particle series were followed by DLS for 84 days at room temperature. Separately, a sample shipped from Australia to Chicago and stored on a bench for over six months measured 77 nm with PDI 0.19.
Low injury in an ALI experiment
In CF ΔF508 iPSC-derived differentiated airway cultures, LDH release after 72 hours remained close to the untransfected control across the tested NCPP formulations.
Model- and dose-specific result, not a claim of universal non-toxicity.
NCPP transfection has also been observed at a 1 µg dose in tested experimental conditions.
Nucleic-acid formulation: branched peptides associate with negatively charged cargo; zinc-coordinated PEG provides a reversible corona. Peptide architecture, PEG length, dose and cargo are tunable experimental variables.
The platform
Peptide architecture, with controllable formulation choices.
NCPPs use branched peptides incorporating non-canonical amino acids to associate with nucleic-acid cargo. Zinc coordination anchors a reversible PEG coating.
- Branched peptide core — non-viral, non-lipid chemistry
- Adjustable formulation — peptide composition and PEG size offer design variables
- Practical preparation — self-assembly by mixing, without a specialist micromixer
Diagram illustrates the concept rather than a measured atomic structure. Cellular uptake pathways vary with formulation and test conditions.
Live imaging
Watch particles interact with airway tissue.
Microscopy provides a visual account of particle distribution and accumulation over time. Field clearing is consistent with uptake, but imaging alone does not identify the molecular entry route.
00:45 h
Particles dispersed through the mucus layer.
09:35 h
Accumulation near cell surfaces.
14:30 h
Progressive clearing of the imaging field.
Research particle supply
Simple formats for real experiments.
Ready-formulated particles, customer-cargo formulations and research workflows. Direct RUO packs can be ordered below; catalogue-specific SKUs and launch specifications will be agreed with distribution partners.
01 / READY-FORMULATED
Reporter particles
Pre-formulated research reporter particles for initial evaluation, selected to suit the application.
02 / CUSTOM
Your plasmid, our particles
Custom formulation using customer-supplied cargo, with scope, controls and testing agreed in advance.
03 / RESEARCH WORKFLOW
Components & SOP
Discuss component supply and formulation guidance for research teams preparing their own cargo formulations.
For research use only. Not for human or diagnostic use. Availability, pack size, batch specifications and release documentation are subject to confirmation.
Direct research-use supply
Order NCPP particles now.
When conventional reagents cannot deliver, price is irrelevant.
In a tested fully differentiated airway model, NCPPs produced reporter expression while Lipofectamine 2000 produced no detectable expression under the comparison conditions. The opportunity is delivery in models that conventional reagents struggle to transfect—not simply a cheaper reagent.
Pre-formulated research particles are available by direct enquiry. Choose a starting pack; we will confirm the appropriate peptide/cargo formulation, availability and shipping before accepting an order.
US$200
For a first evaluation
Volume on request; coverage depends on the model and dose.
- Sized for a single experiment
- Choice of peptide and cargo subject to confirmation
- Ambient shipping options; shipping charged at cost
US$600
For a research programme
500 µL, approximately 200 µg pDNA-equivalent.
- About 50 ALI insert doses at an example 4 µg dose
- Bulk and custom cargo on request
- Shipping charged at cost
Research use only. Not for human or diagnostic use. Pricing from the previous Loxegen RUO offering; final specifications, stock, stability guidance and shipping are confirmed during ordering. Orders are enquiries, not instant checkout.
Catalogue · Distributor · OEM
Looking for a differentiated research reagent?
We are exploring specialist catalogue, regional distribution and OEM relationships for NCPP research particles. The opportunity combines a distinctive chemistry platform with original evidence, formulation guidance and support for custom customer studies.
Partnerships can begin with a focused RUO range rather than a broad, unsupported catalogue.
What we can build together
- Initial products, target applications and catalogue descriptions
- Product codes, batch traceability, CoAs and release criteria
- Endotoxin, storage, shipping and shelf-life qualification
- Protocols, technical support and safety documentation
- Margins, territories, branding and fulfilment responsibilities
These are launch workstreams to agree with partners, not completed regulatory or product-release claims.
Science + data
Ten years of experiments. A smarter next study.
Loxegen's Optilox Data System (ODS) consolidates historic chemistry, formulation conditions, biological models and recorded outcomes. We use that evidence to guide experimental choices and build better structured datasets.
AI-assisted prioritisation supports scientific judgement. Experimental work establishes actual delivery and cell health.
Particles in motion
Original microscopy video retained from the previous Loxegen website.
About Loxegen
Built on research, not just an idea.
An Australian-developed platform with a decade of research, patent protection, independent experimental contributions and government-supported collaboration. Access to Kinesis at CoLabs strengthens the practical pathway for formulation and product development.
MRFF collaboration
Research support through an A$1.5m+ Medical Research Future Fund-funded collaboration involving UQ and MCRI.
APAC recognition
Most Promising Gene Therapy Pipeline in APAC, 2026.
Australian IP
Australian patent protection and an established development programme.
Andrew Venables
Founder & CEO · commercial strategy, law and finance
Dr Daniel Levy
Branched peptide chemistry and particle design
A/Prof Lisa Kaminskas
Formulation science and experimental validation
Prof David Haylock
Cell biology, stem-cell therapeutics and scientific partnerships
Prof David Ascher
AI, computational biology and experimental design
Get in touch
Tell us what you're working on.
Research particle evaluation, custom plasmid formulation, commissioned studies, distribution or OEM: start a conversation.
Andrew Venables
Founder & CEO
avenables@loxegen.net